REIMBURSEMENT UNRAVELLED: Germany’s new program for outpatient innovation gets up and running
This article was originally published in Clinica
Executive Summary
Germany’s central healthcare products reimbursement authority, the G-BA, recently announced the first three technologies eligible for the Erprobungsregelung (“Trial Regulation”). In this first article in a Clinica series on major European medtech reimbursement issues, Medalliance GmbH’s Ben Modley provides background information about this new program and gives details of the two-stage process for applying to use Erprobungsregelung